Jefferies London Healthcare Conference 2025 November 18, 2025 3:30 AM ESTCompany ParticipantsWilliam Lewis - President, CEO ...

Sanofi and Regeneron’s Dupixent (dupilumab) could be set for its ninth US approval after the drug met all the primary and secondary endpoints in a Phase III study in allergic fungal rhinosinusitis ...

Amgen (AMGN) is a top biotech value pick with strong sales, robust R&D, and resilient growth. Read here for an analysis of ...

Clinicians have a new line of weapons in their arsenal to treat recurring nasal polyps. Over the past year several new monoclonal antibody-based biologic drugs have been approved to treat the ...

The U.S. Food and Drug Administration approved Tezspire (tezepelumab-ekko; Amgen) for the add-on maintenance treatment of inadequately controlled chronic rhinosinusitis with nasal polyps (CRSwNP) in ...

Findings showed treatment with tezepelumab significantly reduced the size of nasal polyps and nasal congestion compared with placebo. The Food and Drug Administration (FDA) has approved Tezspire ® ...

Tezspire (tezepelumab-ekko) is a prescription medicine used to treat inflammatory conditions of the airways, such as severe asthma. The FDA has now approved it as an add-on treatment for adults and ...

Approval broadens indication for TEZSPIRE to a second disease characterized by epithelial-driven inflammation WILMINGTON, Del.--(BUSINESS WIRE)--AstraZeneca and Amgen’s TEZSPIRE® (tezepelumab -ekko) ...

"For people living with CRSwNP, every breath can feel like a struggle, and many endure years of recurring symptoms and surgeries without significant relief. The approval of TEZSPIRE represents a ...

About Chronic Rhinosinusitis with Nasal Polyps (CRSwNP [nasal polyps]) CRSwNP is a complex inflammatory disorder characterized by persistent inflammation of the nasal mucosa accompanied by benign ...